Company Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 10:36:30 2024-05-23 am EDT			5-day change	1st Jan Change
0.83 ^USD	-1.19%		-4.60%	+62.75%

May. 06	Oppenheimer Upgrades Chemomab Therapeutics to Outperform	MT
Apr. 10	Transcript : Chemomab Therapeutics Ltd. - Special Call

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Managers	Title	Age	Since
Adi Mor CEO	Chief Executive Officer	43	11-09-21
Sigal Fattal DFI	Director of Finance/CFO	53	19-12-31
Matthew B. Frankel CTO	Chief Tech/Sci/R&D Officer	56	22-11-13
Ilan Vaknin CTO	Chief Tech/Sci/R&D Officer	-	22-08-11
Jack Lawler CTO	Chief Tech/Sci/R&D Officer	-	22-01-03
Barbara Lindheim IRC	Investor Relations Contact	-	-
Sharon Hashmueli LAW	General Counsel	-	15-12-31

Members of the board	Title	Age	Since
Neil Cohen BRD	Director/Board Member	60	20-03-31
Nissim Darvish CHM	Chairman	59	21-03-15
Claude Nicaise BRD	Director/Board Member	71	21-03-15
Alan Moses BRD	Director/Board Member	76	21-03-15
Adi Mor CEO	Chief Executive Officer	43	11-09-21
Jill Quigley BRD	Director/Board Member	49	22-06-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	20	14,204,735	705,422 ( 4.966 %)	0	4.966 %

Name	Equities	%	Valuation
OrbiMed Advisors Private Equity 16.45 %	2,241,274	16.45 %	1 M $
Ikarian Capital LLC 1.566 %	213,392	1.566 %	140 625 $
Two Sigma Investments LP 0.2936 %	39,994	0.2936 %	26 356 $
Two Sigma Advisers LP 0.2775 %	37,800	0.2775 %	24 910 $
Kestra Private Wealth Services LLC 0.2293 %	31,241	0.2293 %	20 588 $
Boothbay Fund Management LLC 0.1947 %	26,529	0.1947 %	17 483 $
Two Sigma Securities LLC 0.1922 %	26,185	0.1922 %	17 256 $
RhumbLine Advisers LP 0.1367 %	18,627	0.1367 %	12 275 $
Geode Capital Management LLC 0.0862 %	11,737	0.0862 %	7 735 $
G1 Execution Services LLC 0.0842 %	11,477	0.0842 %	7 563 $

Name	Equities	%	Valuation
Peter Thiel 10.36 %	22,170,180	10.36 %	730 507 $
Apeiron Partners 0.3399 %	727,163	0.3399 %	23 960 $
Centillion Fund, Inc. 0.3091 %	661,370	0.3091 %	21 792 $
Adi Mor 0.2656 %	568,222	0.2656 %	18 723 $
Neil Cohen 0.0707 %	151,218	0.0707 %	4 983 $
Sigal Fattal 0.007012 %	15,002	0.007012 %	494 $
Dale Pfost 0.001168 %	2,500	0.001168 %	82 $
Donald Marvin 0.000935 %	2,000	0.000935 %	66 $
Nissim Darvish 0.000561 %	1,200	0.000561 %	40 $
Jill Quigley 0.000000 %	0	0.000000 %	- $

Chemomab Therapeutics Ltd.

Kiryat Atidim Building 7

6158002, Tel Aviv

+972 77 331 0156

http://www.chemomab.com

address Chemomab Therapeutics Ltd.(CMMB)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.84 USD

Average target price

6.5 USD

Spread / Average Target

+673.81%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CHEMOMAB THERAPEUTICS LTD.	+62.75%	11.93M
VERTEX PHARMACEUTICALS INCORPORATED	+10.41%	115B
REGENERON PHARMACEUTICALS, INC.	+12.76%	106B
BIONTECH SE	-4.45%	24.69B
ARGENX SE	-2.42%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-11.54%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.84%	14.03B
SAREPTA THERAPEUTICS, INC.	+32.24%	12.13B

Bio Therapeutic Drugs